Indoco Remedies Secures FDA Approval for Generic Lacosamide Oral Solution for Epilepsy Treatment
核心洞察
Indoco Remedies received final FDA approval for its generic lacosamide oral solution USP 10 mg/mL, equivalent to UCB's Vimpat oral solution.
The approved medication treats partial-onset seizures (搜索) and primary generalized tonic-clonic seizures (搜索) in adults and children with epilepsy (搜索) aged 4 years and above.
The approval strengthens Indoco's presence in the US generics market, particularly in the neurology segment, supporting the company's commitment to global healthcare delivery.
Indoco Remedies Ltd., a research-oriented pharmaceutical company, has received final approval from the US FDA (搜索) for its Abbreviated New Drug Application (ANDA) for lacosamide oral solution USP, 10 mg/mL. The generic medication is bioequivalent and therapeutically equivalent to the reference listed drug, Vimpat oral solution, 10 mg/mL, manufactured by UCB, Inc.
Therapeutic Applications and Patient Population
Lacosamide oral solution is indicated for treating partial-onset seizures (搜索) and primary generalized tonic-clonic seizures (搜索) in adults and pediatric patients with epilepsy (搜索) who are at least 4 years old. This approval expands treatment options for epilepsy patients by providing a generic alternative to the branded medication.
Manufacturing and Quality Standards
The lacosamide oral solution USP will be manufactured at Indoco's facility located at L-14, Verna Industrial Area, Verna, Goa – 403722 in India. The company operates 11 manufacturing facilities globally, including seven finished dosage form units and four API plants, all supported by a state-of-the-art R&D center and contract research organization. These facilities have received approval from major global regulators, including the USFDA and UK-MHRA.
Strategic Market Impact
"We are excited about the ANDA approval for lacosamide oral solution USP, 10 mg/ml. This approval further reinforces our commitment to delivering high-quality healthcare to patients worldwide," said Aditi Panandikar, Managing Director of Indoco Remedies Ltd.
The approval strengthens Indoco's presence in the US generics market, particularly in the neurology segment, and follows recent regulatory progress for the company's manufacturing facilities. As a fully integrated pharmaceutical company with a global footprint, Indoco maintains a turnover of US$180 million and employs over 6,000 people, including more than 400 skilled scientists and field staff.